Hi, everyone. Thank you so much for joining us at the Jefferies London Conference. My name is Cha Cha Yang. I am a Senior Associate working with Roger Song, my analyst in the Boston office. We cover mid-cap biotech, and it is my pleasure today to welcome
Pleasure to be here.
Sam, maybe we do a high-level introduction for SAB BIO first. Can you just tell us what you guys have accomplished in the last year and what you are looking forward to in 2027?
Yes. SAB BIO is a clinical-stage biopharmaceutical company. We are in a pivotal study for the treatment of type 1 diabetes, and we have a proprietary drug, which is a human anti-thymocyte immunoglobulin or thymocyte-targeting plasma-derived IgG. We are currently in a pivotal study, which should be completing enrollment this month.
Okay, that's very exciting. There's been a lot of increasing spotlight on the T1D space over the last few years, and you guys are specifically focused on that. With a lot of approvals and new innovative data coming out in this space, with your experience at SAB, can you just speak more to how you have seen this disease space evolve, and whether that be from investors, from pharma, patient communities, the excitement in this space that's coming up?
Yes. For many years, a lot of the innovation was around insulin delivery and glucose monitoring, which certainly sort of increased the convenience for the patient. There has been a lot of attention and excitement around islet cell transplant, which is really today a late-stage therapy for patients that have lost all their ability to make their own insulin. Recently, over the last couple of years, there's been more and more focus on first-line treatment for new patients to preserve their ability to make insulin, and that's through immunomodulation. The doctors and the experts, and we've complied with the drug companies, have come to realize that our first obligation for type 1 diabetes patients is to preserve their ability to make insulin.
Like with any autoimmune disease, when you recognize that a patient is not tolerant to a key organ, our goal is to save that organ. Tzield was approved, the first immunomodulator, in June of this year, and now there's an approved therapy to preserve the patient's ability to make insulin, which is doing a lot to educate the medical community and get awareness around there, around the importance of preserving insulin production. We're following close behind with what we believe is a superior product for preservation of the patient's ability to make their own insulin.
Yeah, so you mentioned Tzield, which was an exciting approval. There are a couple other companies that are making these immunomodulators. Can you speak more to how SAB-142 is different from these approaches?
Yes. Tzield, which is the only approved drug, is a monoclonal antibody targeting T cells, and it has shown the ability to preserve C-peptide, which is the key marker for a patient's endogenous insulin production. To date, in clinical trials, it has only shown the ability to preserve C-peptide, but it has not shown clinical endpoints such as HbA1c or insulin use. It also requires 12 days of continuous dosing. Our drug, the human IgG or human anti-thymocyte immunoglobulin, based on the data that we have to date from our own drug and a reference product, is two-day dosing. There's evidence that the drug should reduce HbA1c, a functional or clinical marker, and it's a drug that can be redosed for the life of the patient to continue to provide therapy to maintain insulin production.
You guys are in phase II-B right now, and you have your top-line data coming out in 2027. Can you tell us more about your primary endpoint that you're testing and what the benchmarks for success will look like? More specifically, we'd love to learn more about the historical data that drove your powering assumptions, so if you could speak more to that.
Sure. In this field of immunomodulation for newly diagnosed patients, the primary endpoint, which is really the measure of your drug doing the job, is C-peptide, and we're looking to preserve C-peptide compared to placebo. That's the sign of efficacy in a drug. C-peptide is the measure of endogenous insulin production. The key secondary endpoints are HbA1c, which shows that with that benefit of preserved C-peptide, the patient has better glycemic control, which is meaningful to the patient and the doctor. Sorry, can you just do the part B and part C? I forgot.
Oh, yeah.
the question.
Really just about benchmarks and also more so about, like, what are your historical—
Right. So for benchmarks, Tzield, the approved drug, has shown preservation of C-peptide, but has not shown efficacy or hitting any secondary endpoints. They have not reduced HbA1c, or they haven't shown it. They haven't reduced insulin use. They haven't reduced, or they haven't improved glycemic control as measured by time in range. And we believe we have the ability to do that based on these historical benchmarks. An important foundation for our program is a drug with the same mechanism of action, which is called Thymoglobulin. It's a commercial product for organ transplant. It's sold by Sanofi, and it has been shown to both preserve C-peptide and reduce HbA1c. In the same patient population, in two different clinical trials, randomized double-blinded clinical trials. One is called TN19 and one is called MELD-ATG. Now, that drug, Thymoglobulin, is made in rabbits, and it is a rabbit-derived anti-thymocyte globulin.
Because it is rabbit protein or rabbit IgG, it is highly immunogenic, which leads to serum sickness and AE, which is really undesirable, and it can't be redosed. So it's a one and done. You can't get that drug twice, and this is a chronic disease. Our drug is the same type of drug, but it's fully human, and we've already shown in phase I it is not immunogenic and it does not cause serum sickness. So we believe we can rely on the efficacy as seen with Thymoglobulin, and we've already shown that we have the advantages needed for a good target product profile, which is redosability and no serum sickness.
Now, our clinical trial design was modeled after one of these studies, which was called TN19, in which we had all of the data given to us with permission, and were able to use the variability and the patient inclusion and exclusion criteria to design the study. We designed effectively the same study and powered accordingly as the Thymoglobulin study, which showed both preservation of C-peptide as well as HbA1c, giving us high confidence in our likelihood of success.
That is really exciting. We have talked a little bit about the convenience factor. We talked about the efficacy you are looking at. Can you just tell us more about the safety data that you are expecting to see, and are there any AEs that we should be on the lookout for?
We did a phase I. We presented safety data, and the majority of AEs are infusion-related and resolve a day after the infusion. They are reversible, resolvable, and basically manageable by the doctor. The most common AE is headaches.
If those headaches are accompanied by a fever, they call that grade 1 CRS. The presence of a fever or a flu-like symptom. That is something that is common. It is on target, but it is easily managed with steroids and NSAIDs, and it resolves within a day.
Okay. That is great to know. Safeguard is a phase II-B study, so can you just talk us through the regulatory path, and what you expect the conversations to be with regulators after your top-line release next year?
Yes. We call it a phase II-B because it has some dose ranging. It has a higher dose and a lower dose, both active. For that reason, to be technically accurate, we call it a phase II-B. At the same time, it is a pivotal study. We have agreement with FDA that it is pivotal and can be used for registration. So it's like a phase III. In terms of the results from this trial, if positive, are sufficient to file a BLA and market the drug.
Mm-hmm. That is based on primarily your C-peptide data, is that correct? Not necessarily based on your HbA1c, or can you clarify that?
Yeah, that's a good question. Tzield was approved on one study called PROTECT, in which they showed C-peptide preservation but did not show any clinical benefit, meaning they didn't show any other secondary endpoints. That, it's an accelerated approval. They still have an obligation to show secondary or clinical endpoints. But it is a precedent with FDA that C-peptide is sufficient for an accelerated approval. So, in the event, which we're not planning for, that we only hit on C-peptide, we would be eligible for an accelerated approval.
Based on the Thymoglobulin data and our powering and our design of the study, we also expect to hit HbA1c and hopefully other secondaries, which would be a full approval.
I see. Beyond HbA1c, what other functional data do you think you might be able to present next year?
Well, in terms of when we present top-line data, the only thing I know we're going to do now is C-peptide and HbA1c.
Yeah.
We are also looking at insulin use.
The frequency of hypoglycemic events, which that has a big impact on the patient's life. It's very disruptive, and if you can reduce that's a very meaningful clinical endpoint.
For sure.
As well as time in range. HbA1c has been around for a while and is one way to measure glycemic control. Today, almost all patients use continuous glucose monitoring, and every patient in our clinical trial is required to use continuous glucose monitoring so we can measure the amount of time they spend in a normal range, which is also a very precise indicator of glycemic control.
I see. The potential to file for BLA for accelerated approval just based on C-peptide, let's say in the event that you don't hit on HbA1c, which you said you don't expect, but in case that does happen, w hat is the next step for a full approval?
Well, the next step would be using the SAFEGUARD data, seeing what the trends are or what the delta is in those other endpoints, and with all that information, you can very confidently design a trial to address whatever the shortcomings are, which is most likely power.
Got it.
Then you have an obligation. I like to remind people that, as compared to Sanofi, we are a pre-commercial company, and we would be with an accelerated approval, even though there is an obligation to do another study. The difference between pre-commercial and commercial with revenues is a massive value inflection point, whether it is accelerated or full.
Yeah. That makes a lot of sense. In addition to SAFEGUARD, you guys are also entering in the phase III investigator-led study. Can you tell us more about that study, about the design, about the goals, and about potentially the primary endpoints that we are looking at there?
Yes. That is called the PRISE-hATG study. It is a phase III study, and it was a protocol presented or investigators, which include Mike Haller at the University of Florida and Chantal Mathieu at Leuven in Belgium, were very interested, along with the rest of the T1D community, with treating patients as far along as possible. The PRISE-hATG study is looking at patients up to two years from diagnosis. For context, Tzield is approved in patients within eight weeks of diagnosis, giving a very tight timetable and window for treatment. The SAFEGUARD study is within the first 100 days of diagnosis. All the other clinical research in this sphere of newly diagnosed patients has a very narrow window for treatment and for studying.
The philanthropy community, the patient community, the KOL community, very concerned about excluding all these patients based on what may be arbitrary, which is time from diagnosis. That is where our phase III, the PRISE-hATG study, comes in, and that is why it is funded by Breakthrough, is because the tremendous interest in the academic community. The PRISE-hATG study is a sister study to SAFEGUARD. It is a phase III, and two cohorts are added. One is what we call cohort two, which is from 100 days- 365 days, and one is cohort three, is from 365 days to two years, and that will be compared to cohort one, a synthetic cohort, which is in that first 100 days, which comes from SAFEGUARD. Other than that time from diagnosis, the protocol is identical.
The endpoints are the same, C-peptide preservation, HbA1c as secondary, along with those others, insulin use and time in range.
Can you remind us what the timelines for data release are on that?
We have less insight into that because that is a study where Breakthrough T1D and these academic investigators are running the study.
We don't have as much control over the time it takes to enroll the trial. What I can tell you is that the first patient should be enrolled this quarter, and 72 new patients are needed. It's enrolling at seven sites. Really, because we are one step removed, we're kind of arm's length.
Yeah
We'll look at how they do the first quarter and update everyone quarter- by- quarter to figure out their pace and then be able to estimate when the trial should be done.
Okay. Sure. Makes sense. With the data that is generated from this phase III, how do you expect that to go into regulatory conversations, if at all, for SAB-142, whether that be for potential accelerated approval or full approval?
Firstly, the SAFEGUARD study is our pivotal study, which we can get the drug approved on.
The PRISE-hATG study is extra cohorts that are not included in SAFEGUARD, and so it is kind of a win-win.
If it does not work, it really does not impact our study. Even Tzield is only the first eight weeks, and we are 100 days. We already have a bigger window, can have more market penetration. If PRISE-hATG is successful, if the thesis is correct that time from diagnosis is arbitrary and the drug will work regardless of time from diagnosis, then we expect to be able to expand the label to include patients up to two years. I would think, I do not know, but I would think that if cohort two and three both work, you could make a solid case that time is not relevant and really make the only criteria for treatment C-peptide. The results being positive would just expand the market opportunity and make patient access easier because patients would not have this clock that expires for getting treatment.
Yeah, for sure. The patient journey is tough the first 100 days or so to be able to expand that to give access to more patients would be really exciting.
Yeah.
Do you think that would require you to run an additional trial with the longer diagnosis time, or do you think this data from PRISE-hATG would be sufficient to potentially expand?
PRISE-hATG is the study.
Okay
It is designated by FDA as a phase III. It is powered.
Okay. Sounds great. I know you were talking about Tzield for this presentation, so would love to talk more about that. We know Tzield has been recently approved for Stage 3 T1D. My question really is about how has this shifted the competitive landscape for SAB-142, and how has that shifted the conversations within the T1D space more generally?
Yeah. We've really been following Tzield with full knowledge of their program and their data from the beginning. I mean, we owe a lot to them because they established a regulatory path. What it does is it gets doctors used to prescribing. It educates the healthcare provider community and diabetes educator community about the importance of C-peptide. It's really a paradigm shift in how T1D patients are treated. Prior to Tzield, there was no prescription, there was no treatment for treating the actual disease or disease-modifying therapy. The patients and the doctors simply got into how to measure glucose and how to treat with insulin. Now with Tzield, doctors are getting used to writing a prescription and getting a patient infused. Now, we believe we will have a strong second comer advantage because our differentiation and our competitive advantages are stark.
If we just start with the baseline, Tzield requires 12 days of continuous infusion, which is a very high burden to put on the patients and the doctors, figuring out 12 days of continuous infusion, whereas we're two days. Two days versus 12 days is enough on its own. We hope to have superior efficacy with the secondary endpoints, and we have redosability, so we can offer the patient the promise of continuous dosing and continuous preservation of their beta cells as opposed to just temporary, because Tzield cannot redose. We think they're doing a lot of heavy lifting, a lot of good medical education, and we'll have a strong second comer advantage.
Yeah. Do you have any insights into what the sales uptake is like for Stage 3 T1D? Because historically, Tzield hasn't done particularly well in Stage 2.
Yeah.
Any insight into this new indication expansion?
Well, it is an interesting question, because I think the idea that Tzield didn't do well in Stage 2 was simply from confusion in the market.
The Stage 2 market, and Stage 2 is patients who are asymptomatic, that have the presence of autoantibodies for their pancreas. The only way a patient and their family would find out if they were positive for autoantibodies is if they went out of their way, went to an academic institution, and asked to be tested. It was kind of like a niche product. The Stage 3 market is 10x the size of the Stage 2 market. I think for those who really modeled and forecast that Stage 2 indication, they did quite well. I think they beat expectations. What people in the market, after a $3 billion acquisition, Sanofi paid $3 billion for that drug, had different ideas of what their sales should be, when that sales price was probably more built around assuming a Stage 3 approval.
In Stage 2, I think the last quarter, it had kind of plateaued, was about $25 million, and with the first full quarter in Stage 3, it is like $47 million. I am not giving exact numbers, approximate.
That's a solid first quarter for a biologic and a new indication where doctors are not used to prescribing. We were very encouraged by that, despite the 12-day dosing, which we know they're getting a lot of nos because of that very difficult dosing.
Considering first quarter, difficult target product profile, I think it's encouraging.
Yeah. Enormous commercial opportunity potential here.
Yeah.
We're really reaching the end of our fireside chat. Is there anything that we haven't covered that you'd like to share with the audience today?
Well, I think that T1D has largely been underappreciated because drug companies had insulin franchises, and drug companies without insulin franchises didn't consider themselves type 1 diabetes companies. What Tzield did, and it's very new, it just got approved, is taught everyone that Type 1 diabetes is a major unmet need in autoimmunity and should be considered as an autoimmune drug, where our goal is to save the organ. So, it's kind of an underappreciated space. It's a large unmet medical need with really a large total addressable market, perhaps a $20 billion total addressable market. So, it's really early days for T1D. I think the interest is growing. I think we have the most exciting product next in line, and that will really make a big difference in how people think about T1D.
For the patients and the families and the caregivers, we are going to transform what it means to have T1D.
Completely agree. We haven't really had anything since the discovery of insulin, since Tzield in 1921.
Yeah
Patients have been on insulin for over 100 years with really no other therapeutic.
Right.
This is an exciting space, and excited for SAB in the coming year. Thank you so much.
Thank you. Thanks for your time.